YUHSpace: Dept. of Internal Medicine (내과학교실)

YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

Dept. of Internal Medicine (내과학교실)

Researcher List

Keyword Cloud

Journal Categories

Highly Cited Articles

Trastuzumab in combination with chemotherapy versus chemotherapy alone f...

Yung-Jue Bang ; Eric Van Cutsem ; Andrea Feyereislova ; Hyun C Chung ; Lin Sh... LANCET, Vol.376(9742) : 687-697, 2010

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria ; Yuichiro Ohe ; Johan Vansteenkiste ; Thanyanan Reungwetw... NEW ENGLAND JOURNAL OF MEDICINE, Vol.378(2) : 113-125, 2018

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S.J. Antonia ; A. Villegas ; D. Daniel ; D. Vicente ; S. Murakami ; R. Hui ; ... NEW ENGLAND JOURNAL OF MEDICINE, Vol.377(20) : 1919-1929, 2017

This table browses all dspace content
Issue Date	Title	Journal Title
2025	Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990-2021	AMERICAN JOURNAL OF GASTROENTEROLOGY
2025	Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial	ESMO OPEN
2025	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer	ESMO OPEN
2025	Incidence and risk factors of hepatocellular carcinoma in patients with autoimmune hepatitis in Asia	JHEP REPORTS
2025	BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/ expansion multicenter study	ESMO OPEN
2025	Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC	JTO CLINICAL AND RESEARCH REPORTS
2025	Association of Hysterectomy With Hypertension Incidence in Korean Women: A Nationwide Cohort Study	MAYO CLINIC PROCEEDINGS
2025	A Response to the Letter to the Editor Regarding "Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations	JOURNAL OF THORACIC ONCOLOGY
2025	Mapping and ablation outcomes of extra-pulmonary vein triggers in atrial fibrillation: single-centre retrospective study with consistent provocation protocol	EUROPACE
2025	Advanced echocardiography and cluster analysis to identify secondary tricuspid regurgitation phenogroups at different risk	REVISTA ESPANOLA DE CARDIOLOGIA
2025	Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study	JTO CLINICAL AND RESEARCH REPORTS
2025	APOBEC3A drives deaminase mutagenesis in human gastric epithelium	GENOME RESEARCH
2025	Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study	HEPATOLOGY
2025	Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial)	ESMO OPEN
2025	User-needs based app for patients with inflammatory bowel disease: development and usability study	BMC HEALTH SERVICES RESEARCH
2025	Balancing safety and effectiveness in colonoscopy for older adults: a narrative review	INTESTINAL RESEARCH
2025	LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy	JOURNAL OF THORACIC ONCOLOGY
2025	Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)	BLOOD CANCER JOURNAL
2025	Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study	JOURNAL OF CLINICAL ONCOLOGY
2025	Changes in lung function and exercise capacity are strong predictors of mortality in patients with IPF receiving antifibrotic therapy	FRONTIERS IN MEDICINE